Oregon Psilocybin Data, Heidi Overton’s FDA Nomination, and Johnson & Johnson’s $85 Million Delix Investment

Oregon’s regulated psilocybin services program is associated with substantial self-reported reductions in depression, anxiety, and PTSD symptoms three months after care, alongside high reported safety ratings, but proposed licensing fee increases could threaten its financial viability and worsen access for lower-income clients. The briefing also examines President Donald Trump’s nomination of Heidi Overton to lead the FDA, including proposed changes to federal psychedelic policy that reduced a planned research fund and removed a psychedelic therapy czar while preserving measures to accelerate reviews and rescheduling for some trial-proven drugs. Finally, Johnson & Johnson is set to lead an $85 million Series C investment in Delix Therapeutics, whose 5-MeO-DMT-modeled neuroplastogen DLX-001 is moving toward Phase 2 trials involving at-home dosing. The financing has not yet closed, and the FDA nomination remains uncertain.